Q2 EPS Estimate for Precision BioSciences Cut by Analyst

Precision BioSciences, Inc. (NASDAQ:DTIL) – HC Wainwright lowered their Q2 2025 EPS estimates for shares of Precision BioSciences in a note issued to investors on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.09) for the quarter, down from their previous forecast of ($0.08). HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Precision BioSciences’ Q3 2025 earnings at ($0.38) EPS and FY2025 earnings at ($2.77) EPS.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings results on Thursday, May 15th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($1.78). Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $5.00 million.

Precision BioSciences Stock Performance

NASDAQ DTIL opened at $4.58 on Friday. The company has a market capitalization of $50.78 million, a price-to-earnings ratio of 76.35 and a beta of 1.55. Precision BioSciences has a twelve month low of $3.61 and a twelve month high of $13.32. The stock has a fifty day simple moving average of $4.97 and a 200 day simple moving average of $5.34. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Moloney Securities Asset Management LLC increased its stake in shares of Precision BioSciences by 177.0% in the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock valued at $335,000 after buying an additional 56,100 shares during the period. Commonwealth Equity Services LLC acquired a new position in shares of Precision BioSciences in the fourth quarter worth approximately $48,000. Samalin Investment Counsel LLC bought a new stake in Precision BioSciences in the fourth quarter valued at approximately $59,000. Renaissance Technologies LLC increased its position in Precision BioSciences by 36.2% during the 4th quarter. Renaissance Technologies LLC now owns 109,798 shares of the company’s stock valued at $418,000 after purchasing an additional 29,200 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Precision BioSciences during the 4th quarter valued at approximately $67,000. 37.99% of the stock is owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.